The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management. Klarity connects you with healthcare ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Cancel anytime. Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management.